S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
S&P 500   4,221.02 (+0.99%)
DOW   33,061.57 (+0.47%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) Stock Forecast, Price & News

$0.39
+0.01 (+2.48%)
(As of 04:33 PM ET)
Compare
Today's Range
$0.38
$0.41
50-Day Range
N/A
52-Week Range
$0.38
$0.94
Volume
245,216 shs
Average Volume
388,879 shs
Market Capitalization
$85.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Matinas BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
664.1% Upside
$3.00 Price Target
Short Interest
Healthy
0.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.11) to ($0.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars


MTNB stock logo

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Maxim Group Remains a Buy on Matinas BioPharma (MTNB)
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
Q4 2022 Matinas BioPharma Holdings Inc Earnings Call
See More Headlines

MTNB Price History

MTNB Company Calendar

Last Earnings
3/15/2023
Today
6/01/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:MTNB
CIK
N/A
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+683.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-21,000,000.00
Net Margins
-479.18%
Pretax Margin
-479.16%

Debt

Sales & Book Value

Annual Sales
$3.19 million
Book Value
$0.15 per share

Miscellaneous

Free Float
197,277,000
Market Cap
$83.23 million
Optionable
Not Optionable
Beta
2.03

Key Executives

  • Jerome D. Jabbour
    President, Chief Executive Officer & Director
  • Keith A. Kucinski
    Chief Financial Officer
  • Raphael J. Mannino
    Chief Scientific Officer & Senior Vice President
  • James J. Ferguson
    Chief Medical Officer
  • Hui Liu
    Chief Technology Officer













MTNB Stock - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings
or view top-rated stocks.

What is Matinas BioPharma's stock price forecast for 2023?

2 analysts have issued 12-month target prices for Matinas BioPharma's shares. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 683.1% from the stock's current price.
View analysts price targets for MTNB
or view top-rated stocks among Wall Street analysts.

How have MTNB shares performed in 2023?

Matinas BioPharma's stock was trading at $0.5563 at the beginning of 2023. Since then, MTNB stock has decreased by 31.1% and is now trading at $0.3831.
View the best growth stocks for 2023 here
.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,400,000 shares, a decline of 14.1% from the April 30th total of 1,630,000 shares. Based on an average daily trading volume, of 444,200 shares, the short-interest ratio is presently 3.2 days.
View Matinas BioPharma's Short Interest
.

When is Matinas BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our MTNB earnings forecast
.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The company earned $1.06 million during the quarter, compared to analyst estimates of $1.10 million. Matinas BioPharma had a negative trailing twelve-month return on equity of 54.49% and a negative net margin of 479.18%.

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.96%), BlackRock Inc. (1.14%), Private Advisor Group LLC (0.09%), Renaissance Technologies LLC (0.08%), Global Retirement Partners LLC (0.05%) and Modera Wealth Management LLC (0.04%).
View institutional ownership trends
.

How do I buy shares of Matinas BioPharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.38.

How much money does Matinas BioPharma make?

Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $83.23 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -